High Quality Lastest Price of Bictegravir Sodium 1807988-02-8, Competitive API Bictegravir Sodium1807988-02-8, CAS Number 1807988-02-8 Suppliers in China

Home > Products > Anti-Hiv Drug > Anti-HIV Drug Bictegravir Sodium GS-9883; GS 9883; GS9883; GS-9883-01 CAS Number 1807988-02-8

Anti-HIV Drug Bictegravir Sodium GS-9883; GS 9883; GS9883; GS-9883-01 CAS Number 1807988-02-8

Anti-HIV Drug Bictegravir Sodium GS-9883; GS 9883; GS9883; GS-9883-01 CAS Number 1807988-02-8

    Terms of Trade: CIF
    Min. Order: 1 Kilogram
    Delivery Time: 15 Days
    Packaging: As required
    Productivity: 10KG/M
    Transportation: Air
    Place of Origin: CHINA
    Certificate: Technical Support

Basic Info

Model No.: 1807988-02-8

Product Description

Bictegravir sodium CAS Number is 1807988-02-8. The FDA approved the Bictegravir sodium combination as a new Anti-Hiv Drug on February 12, 2018. Some professionals expect Bictegravir sodium combination CAS Number 1807988-02-8 has the sales value more than $5 billion in 2022. The drug is the latest development of AIDS drugs by GileadSciences. The company's CEO, John Milligan, believes this will be the best drug ever. It will become the "most important product" in the AIDS market.
Relevant clinical information shows that the first phase of clinical research included 20 adults with chronic HIV infection. Participants were either receiving antiretroviral therapy or were experienced in treatment, but had not used integrase inhibitors before and did not take antiretroviral drugs for at least 12 weeks. Except one people, All were white man, with an average age of 35. At baseline, their mean CD4 count was approximately 440 cells/mm3 and the mean HIV RNA level was 4.4 log10 copies/ml. Participants were randomly assigned to 5, 25, 50, 100 mg of the Bictegravir sodium combination and placebo groups for 10 days on an empty stomach once a day. Drug resistance testing is performed between baseline and maximum dose. On day 11, the Bictegravir sodium combination resulted in a rapid dose-dependent decrease in viral load from -1.45 to -2.43 log10, while there was no change in the placebo group. In all treatment groups of the Bictegravir sodium combination, viral load decreased throughout the treatment period, from 50 mg on day 14 to 100 mg on day 17. At the end of treatment, one participant at a dose of 50 mg and two participants at a dose of 100 mg inhibited the virus below 50 copies/ml. There were no serious adverse reactions in the different dose groups for the side effects of the Bictegravir sodium combination due to side effects.

Thera. Category:Integrase Inhibitor

Cas No.:1807988-02-8

Synonyms:Bictegravir;GS-9883; Bictegravir (GS-9883)




Assay: ≥99%

Packing:Export worthy packing

Material Safety Data Sheet:Available on request

Taizhou Volsen Chemical Co., Ltd.


Taizhou Volsen Chemical Co., Ltd. is professional in R&D, producing and marketing Pharmaceutical raw materials, pharmaceutical intermediates in China. VOLSEN consists of about 100 experienced employees including 3 PhD and 10 Master, and 35000 sqm facilities including research laboratories, kilo lab, pilot plant and full manufacturing plant,

VOLSEN R&D specialists, quality manager and sales with abundance experience make sure products are reliable and service is professional. The producing person inspect every step of the whole process and check up the quality strictly, in order to insure every batch of raw material achieve the standard of EP,CP, JP,BP etc.Matching to the diversified requirements of companies VOLSEN is steadily marching to reach the peaks.

Volsen owns a professional custom synthesis department, with more than 15 senior scientific research chemical personnels who have a graduate degree or above. We also have an independent scientific management system. Our company integrates years of production experiences and talent reserves that forms a strong R&D production capacity, furthermore we could undertake various chemicals customizations from kg to ton relying on the existing production base and equipment.

Manufacturing Unit is equipped with a facility of progressive reeducation of emissions, effluents and discharge of waste material that are known to have a negative impact on the environment. Besides, Laboratory as well as plant is equipped with latest Machinery, Equipments, Technical personnel & Means of communications.

Due to supply of reliable quality, efficient follow up, scheduled delivery and prompt response to any matter, company wins good comments from customers.

We aimed at delivering real business value to our clients. For any interest, pls call on us or email us to get our best services.

Company Info

  • Company Name: Taizhou Volsen Chemical Co., Ltd.
  • Representative: Mr Chen
  • Product/Service: Favipiravir Intermediates , Arbidol Intermediates , Relugolix Intermediates , Vilanterol Intermediates , Remdesivir Intermediates , Umeclidinium Bromide
  • Capital (Million US $): 60000000RMB
  • Year Established: 2002
  • Total Annual Sales Volume (Million US $): Above US$100 Million
  • Export Percentage: 91% - 100%
  • Total Annual Purchase Volume (Million US $): Below US$1 Million
  • No. of Production Lines: 5
  • No. of R&D Staff: 91 -100 People
  • No. of QC Staff: 11 -20 People
  • OEM Services Provided: yes
  • Factory Size (Sq.meters): 30,000-50,000 square meters
  • Factory Location: Dongying Economic Development Zone , Dongying, Shandong,China
  • Contact Person: Ms. Amy Cheng
  • Tel: 86-576-88869393
Email to this supplier
  • *Subject:
  • To:

  • *Messages:
    Your message must be between 20-8000 characters